2020
Bleeding with vascular endothelial growth factor tyrosine kinase inhibitor: A network meta-analysis
Das A, Mahapatra S, Bandyopadhyay D, Samanta S, Chakraborty S, Philpotts LL, Jahangir E, Roy B. Bleeding with vascular endothelial growth factor tyrosine kinase inhibitor: A network meta-analysis. Critical Reviews In Oncology/Hematology 2020, 157: 103186. PMID: 33309571, DOI: 10.1016/j.critrevonc.2020.103186.Peer-Reviewed Original ResearchConceptsTyrosine kinase inhibitorsHemorrhagic eventsVEGFR-TKICancer patientsOdds ratioVascular endothelial growth factor tyrosine kinase inhibitorVascular endothelial growth factor receptor tyrosine kinase inhibitorsGrowth factor receptor tyrosine kinase inhibitorsReceptor tyrosine kinase inhibitorsKinase inhibitorsHigh-grade bleedingSide effect profileStandard chemotherapeutic regimenFirst-choice treatmentConfidence intervalsRandom-effects modelTypes of cancerVEGFR-TKIsChemotherapeutic regimenPrimary outcomeClinical trialsHigh riskPlaceboComparative riskPatients
2019
Neuropathy with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A meta-analysis.
Roy B, Das A, Ashish K, Bandyopadhyay D, Maiti A, Chakraborty S, Stone ME, Philpotts LL, Nowak RJ, Patwa HS. Neuropathy with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A meta-analysis. Neurology 2019, 93: e143-e148. PMID: 31167931, DOI: 10.1212/wnl.0000000000007743.Peer-Reviewed Original ResearchConceptsPeripheral neuropathyVEGFR-TKISensory neuropathyRelative riskVascular endothelial growth factor receptor tyrosine kinase inhibitorsGrowth factor receptor tyrosine kinase inhibitorsTyrosine kinase inhibitor useReceptor tyrosine kinase inhibitorsRisk of neuropathyStandard chemotherapeutic regimenVEGFr-TKI therapyVEGFR-TKI treatmentTyrosine kinase inhibitorsVEGFR-TKIsChemotherapeutic regimenInhibitor usePrimary outcomeClinical trialsNeuropathyHigh riskPatientsKinase inhibitorsCancerStrong associationIndividual treatment